🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessCost comparison: brand vs compounded — what worked for you?

Cost comparison: brand vs compounded — what worked for you?

JakeBK_lifts Mon, Nov 3, 2025 at 4:35 PM 12 replies 1,283 viewsPage 1 of 3
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
JakeBK_lifts
Member
523
2,345
Jul 2024
Brooklyn, NY
Nov 3, 2025 at 4:35 PM#1

Writing this once so I can stop repeating it across threads. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

The condition it depends on

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

The bit I cannot resolve on my own is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission. Tell me what I have not thought of.

— JakeBK_lifts · corrections welcome and will be edited into this post with credit
38 8TrialTracker_MD, JennaRN, LabKate and 35 others
Reply Quote Save Share Report
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Nov 3, 2025 at 4:58 PM#2
JakeBK_lifts said:
They are two different exemptions from the same federal requirements and they buy different things.

JakeBK_lifts has the substance of this right. The condition it depends on is worth stating. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Nov 3, 2025 at 8:58 PM
37 7RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 34 others
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Nov 3, 2025 at 5:21 PM#3
JakeBK_lifts said:
They are two different exemptions from the same federal requirements and they buy different things.

I read this differently from JakeBK_lifts, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

36 6RetaRick_CA, JenPlateau, SallyK_inj and 33 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Nov 3, 2025 at 5:44 PM#4

Taking the question as asked, rather than the general version of it. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

35 5SkepticalSean, Dr.CardioMD, EndoResFellow and 32 others
Reply Quote Save Share Report
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
Nov 3, 2025 at 7:51 PM#5
DebRD_ATL said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreed, and coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.

34 4ChrisMacros, KetoKyle, CanadaChris and 31 others
Reply Quote Save Share Report

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register